Literature DB >> 27356519

Benzodiazepine and neuroactive steroid combinations in rats: anxiolytic-like and discriminative stimulus effects.

Barak W Gunter1,2, Sherman A Jones1,2, Ian A Paul1,2, Donna M Platt1,2, James K Rowlett3,4,5.   

Abstract

RATIONALE: Benzodiazepines are effective anxiolytics, hypnotics, and anticonvulsants but unwanted side effects, including abuse potential, limit their use. A possible strategy to increase the therapeutic index of this drug class is to combine benzodiazepines with neuroactive steroids.
OBJECTIVES: The present study evaluated the extent to which combinations of benzodiazepines (triazolam, clonazepam) and neuroactive steroids (pregnanolone, ganaxolone) induced additive, supra-additive, or infra-additive effects in an elevated zero maze and a drug discrimination procedure in rats.
METHODS: Male Sprague-Dawley rats (N = 7/group) were placed into an elevated zero maze apparatus following injections of multiple doses of triazolam and pregnanolone, alone and combined, or clonazepam and ganaxolone, alone and combined. These drugs/drug combinations also were evaluated in rats (N = 8) trained to discriminate triazolam (0.1 mg/kg, i.p.) from vehicle. Drug interactions were evaluated using isobolographic and dose-addition analysis.
RESULTS: In the elevated zero maze, all drugs engendered dose-dependent increases in time spent in the open quadrant when administered alone. Triazolam and pregnanolone, as well as clonazepam and ganaxolone combinations produced additive or supra-additive effects depending on the fixed-proportion that was tested. In triazolam discrimination, all drugs engendered dose-dependent increases in triazolam-lever responding. In combination, triazolam and pregnanolone and clonazepam and ganaxolone produced predominantly additive discriminative stimulus effects, except for one fixed proportion of clonazepam and ganaxolone which had supra-additive effects.
CONCLUSIONS: Although drug interactions depended on the constituent drugs, the combination tested, and the behavioral endpoint; a combination was identified that would be predicted to result in supra-additive anxiolytic-like effects with predominantly additive discriminative stimulus effects.

Entities:  

Keywords:  Anxiolysis; Benzodiazepine; Drug discrimination; Elevated zero maze; GABAA receptor; Neuroactive steroid

Mesh:

Substances:

Year:  2016        PMID: 27356519      PMCID: PMC6334648          DOI: 10.1007/s00213-016-4369-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  43 in total

Review 1.  Discriminative stimulus effects of drugs acting at GABA(A) receptors: differential profiles and receptor selectivity.

Authors:  D J Sanger; G Griebel; G Perrault; Y Claustre; H Schoemaker
Journal:  Pharmacol Biochem Behav       Date:  1999-10       Impact factor: 3.533

Review 2.  Drug synergism: its detection and applications.

Authors:  R J Tallarida
Journal:  J Pharmacol Exp Ther       Date:  2001-09       Impact factor: 4.030

3.  Behaviorally selective effects of neuroactive steroids on plus-maze anxiety in mice.

Authors:  R J Rodgers; N J Johnson
Journal:  Pharmacol Biochem Behav       Date:  1998-01       Impact factor: 3.533

4.  Discriminative stimulus effects of zolpidem in pentobarbital-trained subjects: I. Comparison with triazolam in rhesus monkeys and rats.

Authors:  J K Rowlett; W L Woolverton
Journal:  J Pharmacol Exp Ther       Date:  1997-01       Impact factor: 4.030

5.  Benzodiazepine use in the United States.

Authors:  Mark Olfson; Marissa King; Michael Schoenbaum
Journal:  JAMA Psychiatry       Date:  2015-02       Impact factor: 21.596

6.  Differential interactions engendered by benzodiazepine and neuroactive steroid combinations on schedule-controlled responding in rats.

Authors:  Barak W Gunter; Donna M Platt; James K Rowlett
Journal:  Pharmacol Biochem Behav       Date:  2015-08-06       Impact factor: 3.533

7.  Effects of benzodiazepine receptor ligands and ethanol in rats trained to discriminate pregnanolone.

Authors:  K E Vanover
Journal:  Pharmacol Biochem Behav       Date:  2000-11       Impact factor: 3.533

8.  Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy.

Authors:  Vincent A Pieribone; Julia Tsai; Christine Soufflet; Elisabeth Rey; Ken Shaw; Earl Giller; Olivier Dulac
Journal:  Epilepsia       Date:  2007-07-18       Impact factor: 5.864

9.  Using drug combinations to assess potential contributions of non-GABAA receptors in the discriminative stimulus effects of the neuroactive steroid pregnanolone in rats.

Authors:  Amy K Eppolito; Hanna R Kodeih; Lisa R Gerak
Journal:  Physiol Behav       Date:  2014-07-26

10.  Discriminative stimulus effects of pregnanolone in rhesus monkeys.

Authors:  Lisa R Gerak; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2013-08-15       Impact factor: 4.530

View more
  4 in total

1.  The Actions of Drug Combinations on the GABAA Receptor Manifest as Curvilinear Isoboles of Additivity.

Authors:  Daniel J Shin; Allison L Germann; Joe Henry Steinbach; Gustav Akk
Journal:  Mol Pharmacol       Date:  2017-08-08       Impact factor: 4.436

2.  Self-administration and behavioral economics of second-generation synthetic cathinones in male rats.

Authors:  S L Huskinson; J E Naylor; E A Townsend; J K Rowlett; B E Blough; K B Freeman
Journal:  Psychopharmacology (Berl)       Date:  2016-11-28       Impact factor: 4.530

3.  Isobolographic Analysis of Antiseizure Activity of the GABA Type A Receptor-Modulating Synthetic Neurosteroids Brexanolone and Ganaxolone with Tiagabine and Midazolam.

Authors:  Shu-Hui Chuang; Doodipala Samba Reddy
Journal:  J Pharmacol Exp Ther       Date:  2019-12-16       Impact factor: 4.030

4.  Enhanced GABAergic actions resulting from the coapplication of the steroid 3α-hydroxy-5α-pregnane-11,20-dione (alfaxalone) with propofol or diazepam.

Authors:  Lily Q Cao; Michael C Montana; Allison L Germann; Daniel J Shin; Sampurna Chakrabarti; Steven Mennerick; Carla M Yuede; David F Wozniak; Alex S Evers; Gustav Akk
Journal:  Sci Rep       Date:  2018-07-09       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.